217 related articles for article (PubMed ID: 31747358)
1. Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage.
Benson C; Emond B; Lefebvre P; Lafeuille MH; Côté-Sergent A; Tandon N; Chow W; Dunn K
J Manag Care Spec Pharm; 2020 Feb; 26(2):129-141. PubMed ID: 31747358
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus.
Benson C; Emond B; Romdhani H; Lefebvre P; Côté-Sergent A; Shohoudi A; Tandon N; Chow W; Dunn K
J Manag Care Spec Pharm; 2020 Feb; 26(2):117-128. PubMed ID: 31747357
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV.
Dunn K; Lafeuille MH; Jiao X; Romdhani H; Emond B; Woodruff K; Pesa J; Tandon N; Lefebvre P
J Manag Care Spec Pharm; 2018 Oct; 24(10):1040-1051. PubMed ID: 29877140
[TBL] [Abstract][Full Text] [Related]
4. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
5. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
6. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
Trickey A; Zhang L; Gill MJ; Bonnet F; Burkholder G; Castagna A; Cavassini M; Cichon P; Crane H; Domingo P; Grabar S; Guest J; Obel N; Psichogiou M; Rava M; Reiss P; Rentsch CT; Riera M; Schuettfort G; Silverberg MJ; Smith C; Stecher M; Sterling TR; Ingle SM; Sabin CA; Sterne JAC
Lancet HIV; 2022 Jun; 9(6):e404-e413. PubMed ID: 35659335
[TBL] [Abstract][Full Text] [Related]
7. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
[TBL] [Abstract][Full Text] [Related]
8. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study.
Jacobson K; Ogbuagu O
Medicine (Baltimore); 2018 Oct; 97(43):e13016. PubMed ID: 30412140
[TBL] [Abstract][Full Text] [Related]
9. Economic Outcomes of First-Line Regimen Switching Among Stable Patients with HIV.
Rosenblatt L; Buikema AR; Seare J; Bengtson LGS; Johnson J; Cao F; Villasis-Keever A
J Manag Care Spec Pharm; 2017 Jul; 23(7):725-734. PubMed ID: 28650246
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
11. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
12. Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases.
Mesa-Frias M; Rossi C; Emond B; Bookhart B; Anderson D; Drummond S; Wang J; Lefebvre P; Lamerato LE; Lafeuille MH
J Manag Care Spec Pharm; 2022 Jul; 28(7):753-765. PubMed ID: 35503888
[No Abstract] [Full Text] [Related]
13. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States.
Korsnes JS; Goodwin BB; Murray M; Candrilli SD
Ann Pharmacother; 2016 Dec; 50(12):989-1000. PubMed ID: 27439947
[TBL] [Abstract][Full Text] [Related]
15. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization and costs in patients with HIV-1 who switched first-line antiretroviral therapy.
Mao J; Johnson MP; McPheeters JT; Prajapati G; Beyer AP
Curr Med Res Opin; 2019 Nov; 35(11):1945-1953. PubMed ID: 31311342
[No Abstract] [Full Text] [Related]
17. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
18. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
[No Abstract] [Full Text] [Related]
19. Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine.
Nelson RE; Ma J; Crook J; Knippenberg K; Nyman H; Paul D; Esker S; LaFleur J
J Manag Care Spec Pharm; 2018 Oct; 24(10):1052-1066. PubMed ID: 30247099
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
